US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Defiance Autism Impact ETF

26.96

-0.2079-0.77%

Volume:189

Turnover:5.10K

Market Cap:1.35M

PE:- -

High:26.96

Open:26.96

Low:26.96

Close:27.17

52wk High:29.12

52wk Low:24.54

Shares:50.00K

Float Shares:50.00K

Volume Ratio:5.75

T/O Rate:0.38%

Dividend:0.01

Dividend Rate:0.02%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Qianli Intelligent Driving's ASD System Surpasses 530,000 Installations, Integrated into 19 Models Including Smart

Neurotech raises $4.5m to fund pivotal ASD Phase III trial

Press Release: Oryzon Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/ASD"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ASD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASD\",,,,,undefined,":{"symbol":"ASD","market":"US","secType":"STK","nameCN":"Defiance Autism Impact ETF","latestPrice":26.96,"timestamp":1789056179365,"preClose":27.1679,"halted":0,"volume":189,"delay":0,"changeRate":-0.007652413326020732,"floatShares":50000,"shares":50000,"eps":0,"marketStatus":"Trading","change":-0.2079,"latestTime":"09-10 12:06:49 EDT","open":26.96,"high":26.96,"low":26.96,"amount":5098.069935,"amplitude":0,"askPrice":27.02,"askSize":200,"bidPrice":26.95,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789070400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":27.1679,"nav":27.31,"aum":1365500,"dividendRate":0.000221,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.335,"preClose":27.1679,"latestTime":"16:10 EDT","volume":6,"amount":163.0074,"timestamp":1788984604382,"change":0.1671,"changeRate":0.006151,"amplitude":0},"volumeRatio":5.753553},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASD\",,,,,undefined,":{"symbol":"ASD","floatShares":50000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":5.753553,"shares":50000,"dividePrice":0.00597,"high":26.96,"amplitude":0,"preClose":27.1679,"low":26.96,"week52Low":24.54,"pbRate":"--","week52High":29.12,"institutionHeld":0,"latestPrice":26.96,"eps":0,"divideRate":0.000221,"volume":189,"delay":0,"ttmEps":0,"open":26.96,"prevYearClose":29.12,"prevWeekClose":27.7374,"prevMonthClose":27.6173,"prevQuarterClose":26.76,"fiveDayClose":27.895,"twentyDayClose":27.7856,"sixtyDayClose":24.8631},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASD\",params:#limit:5,,,undefined,":[{"date":"2026-06-24","symbol":"ASD","amount":0.00597,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-24","defaultRemindTime":1782307800000,"name":"Defiance Autism Impact ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-24","currency":"USD","dateTimestamp":1782273600000,"payDate":"2026-06-25"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASD\",market:\"US\",,,undefined,":[{"executeDate":"2026-06-24","recordDate":"2026-06-24","paymentDate":"2026-06-25","value":0.00597,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASD\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASD\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659162663","title":"Press Release: MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162663","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162663?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"trial of ML-007C-MA in adults with schizophrenia experiencing an acute. exacerbation of psychosis. The trial met its primary endpoint, with the. 210/3 mg twice-daily dose demonstrating a statistically significant and. clinically meaningful reduction in PANSS total score compared with. -- ML-007C-MA also demonstrated improvement on a prespecified. impairment and significant separation on key secondary endpoints,including CGI-S and the PANSS Marder positive factor.-- ML-007C-MA was generally well tolerated, with no serious or drug-related. severe adverse events and low rates of GI-related discontinuations. Its. clinical profile, including simple initiation, 99% of patients reaching","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASD","IE00BQXX3C00.GBP","LU1316542783.SGD","MA","LU0868494617.USD","LU2168564222.USD","IE00B1XK9C88.USD","ADP","LU0006306889.USD","UYG","XLF","IPAY","IE00BYQQ9H92.USD","LU1236620750.USD","IE00B775H168.HKD","BK4613","LU2764262908.HKD","FDFF","LU2417539215.USD","LU0174119429.USD","LU0965509010.AUD","IYG","STBQ","BK4559","LU2361044865.SGD","LU1718418525.SGD","IE000WAW04H5.SGD","LU0061474705.USD","LU0353189763.USD","BK4585","FNCL","LATR","LU1145028129.USD","MPLT","LU0672654240.SGD","LU2360107671.USD","LU0234570918.USD","LU2023250504.SGD","VFH","IE0005OL40V9.USD","LU0056508442.USD","LU1989764748.USD","LU2347655073.USD","LU1623119135.USD","LU0942090050.USD","LU2404859667.USD","LU1084165304.USD","IE00BJJMRX11.SGD","IE000F7OJYX1.SGD","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136535851","title":"Qianli Intelligent Driving's ASD System Surpasses 530,000 Installations, Integrated into 19 Models Including Smart","url":"https://stock-news.laohu8.com/highlight/detail?id=1136535851","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136535851?lang=en_us&edition=fundamental","pubTime":"2026-08-08 16:20","pubTimestamp":1786177220,"startTime":"0","endTime":"0","summary":"Qianli Intelligent Driving has announced that its ASD 4.0 assisted driving system has been production-ready and launched in the new smart #1, following its earlier integration in the smart #6. This...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656886125","title":"Neurotech raises $4.5m to fund pivotal ASD Phase III trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2656886125","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656886125?lang=en_us&edition=fundamental","pubTime":"2026-08-04 07:38","pubTimestamp":1785800292,"startTime":"0","endTime":"0","summary":"An announcement from Neurotech International ( ($AU:NTI) ) is now available. Neurotech International has secured binding commitments for a $4.5 mil...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurotech-raises-4-5m-to-fund-pivotal-asd-phase-iii-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurotech-raises-4-5m-to-fund-pivotal-asd-phase-iii-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["III","BK4134","ASD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654704201","title":"Press Release: Oryzon Reports Financial Results and Corporate Update for Half Year Ended June 30th, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2654704201","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654704201?lang=en_us&edition=fundamental","pubTime":"2026-07-28 02:23","pubTimestamp":1785176580,"startTime":"0","endTime":"0","summary":"-- Positive clinical data presented at EHA for iadademstat in first line. in 100% ORR, 89% CRc and 78% CR, including in patients with TP53 or RAS. mutations; the triplet continued to demonstrate a favorable safety. gilteritinib continued to show a favorable safety profile and a high CRc. -- Enrollment initiated in Phase II trial of iadademstat in essential. -- U.S. patent granted for vafidemstat in borderline personality disorder. -- Cash position as of June 30, 2026 was $16.7 million ,excluding the gross proceeds of EUR12.0 million  raised in. -- On July 1, 2026, the company entered into a financing agreement with. COFIDES with a commitment to invest EUR25 million in future capital","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4144","SCD","BK4581","ORR","BK4161","ASD","ENFR","NCI","EIPI","BK4590","CR","BK4588","MDST","TNGY","UMI","AMZA","AMLP","BK4561","ET","MLPA","TPZ","BK4202","USAI","BK4585","EMLP","EIPX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ASD\",params:#limit:6,delay:false,,,undefined,":[]}}